Nasal Pneumococcal Vaccine
Pneumococcal disease (serotype-independent)
Pre-clinicalActive
Key Facts
Indication
Pneumococcal disease (serotype-independent)
Phase
Pre-clinical
Status
Active
Company
About Abera Bioscience
Abera Bioscience is a clinical-stage biotech advancing a modular OMV platform for nasal vaccine delivery. Its lead program is a serotype-independent pneumococcal vaccine preparing for Phase 1, with a preclinical influenza candidate and platform potential for other infectious diseases. The company's strategy is to develop candidates to late preclinical/early clinical phases before seeking licensing partners, supported by non-dilutive funding from EU grants and organizations like CEPI. Leadership includes CEO Maria Alriksson and CSO Mats Lundgren, with foundational science from Prof. Joen Luirink.
View full company profile